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Introduction 37 
As of May, 7Th the Italian National Institute of Health reported 3,752 cases of Severe Acute 38 
Respiratory Syndrome associated with Coronavirus 2 (SARS-CoV-2) in Italian children aged less 39 
than 18 years, 140 of them requiring hospital admission. 40 
Since the first outbreak a global effort has been made to collect clinical and laboratory findings on 41 
patients with SARS-CoV-2 infection. The lower airway is the primary target of the infection, 42 
however the disease spectrum in adults goes from asymptomatic subjects to sever illness 43 
including 5.0% subjects requiring ICU admission, 2,3% who underwent invasive mechanical 44 
ventilation, and 1.4% who died (1).  Data suggest that children are less likely to develop severe 45 
symptoms compared to adults (2). Also, there are growing evidence of clinical manifestations 46 
other than acute respiratory syndrome in paediatrics suggesting that Coronavirus Diseases-19 47 
(COVID-19) spectrum and pathogenesis in children are yet to be unravel. In this report we describe 48 
the results of our preliminary analysis of a cohort of hospitalized pediatrics COVID-19 patients 49 
focusing on mode of presentation, presence of comorbidities, severity of disease and early 50 
outcome.  51 
Material and Methods  52 
We conducted a multicenter retrospective analysis of clinical record of SARS-CoV-2 infected 53 
children in 23 different sites in Italy.  54 
From February 21st, 2020 to May 1st, 2020 subjects aged less than 18 years with a positive result 55 
on high throughput sequencing or real-time reverse-transcriptase–polymerase-chain-reaction (RT-56 
PCR) assay of nasal/pharyngeal swab specimens were included. 57 
The study was approved by the ethical committees of the coordinating center in Milan (protocol 58 
number 2020/ST/061).  59 
Data regarding recent exposure history, clinical symptoms or signs, and laboratory findings on 60 
admission were extracted using a common clinical record form. Radiologic assessments and 61 
laboratory testing were performed according to the clinical care needs of the patient. 62 
The Student’s t test, the χ² method, and Fisher’s exact test were used as appropriate for statistical 63 
analysis to compare continuous and categorical variables. A p value < 0.05 was chosen as cutoff 64 
for significance. Data were analyzed with StataMed (version 12.0). 65 
Results  66 
Overall, 127 children were included; 44 were female (34.9%) and the median age was 4.8 years 67 
(IQR 0.3-8.5); 57 (45%) aged less than 12 months. 68 
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Eight out 127 (6.7%) were admitted to ICU, 14 out of 127 (12%) required oxygen therapy, 5 (4%) 69 
noninvasive ventilation, and 1 patient required mechanical ventilation during the hospitalization. 70 
The severity of the COVID-19 in our children was defined using previously published criteria (3); 71 
7,9%, 48.8% and 27,7% of their clinical features were defined respectively as asymptomatic, mild 72 
or moderate accounting for 84.4% of our cohort; 8.7% was severe and 7.1% was critical.   73 
Age class, sex, and ethnic group did not show a different distribution among the severity 74 
categories (p= 0.57, p=0.62, p=0.375 Fisher exact test; table1). 75 
Twenty out 127 patients (15.7%) had at least one comorbidity. Five (3.9%) had chronic cardiac 76 
condition, 4 (3.1%) had gastrointestinal disorder, 3 (2.4%) were obese, 2 (1.6%) had chronic kidney 77 
disease, chronic neurological disorder and immunological condition respectively. Only one 78 
medically complex patient (defined as children who required long term dependence on life 79 
support) was included. Comorbidities distribution was not different among severity classes 80 
(p=0.08 Fisher exact test). Moreover, the ICU admission rate was similar in patients with 81 
comorbidities and those without (p=0.115 Fisher exact test). 82 
The most common symptoms reported on admission were fever (82,7%), cough (48%) and 83 
rhinorrhea (38%). Seventy-seven out of 127 (60.6%) presented with respiratory symptoms (cough, 84 
rhinorrhea, wheezing, dyspnea). 85 
Thirty-six out 127 (28,3%) had gastrointestinal symptoms (vomit, diarrhea, abdominal pain), of 86 
them twenty-eight (22%) had diarrhea, 12 (9,4%) vomit, 8 (6.3%) abdominal pain.  87 
The presence of gastrointestinal symptoms at the admission was differently distributed 88 
throughout severity classes (p=0.006). Having gastrointestinal symptoms was more frequently 89 
associated with severe and critical phenotype (p=0.029). Interestingly, a history of gastrointestinal 90 
symptoms was positively associated with cardiac involvement as clinical complications, in 91 
presence of other symptoms (p=0.007) or alone (p=0.004).   92 
Roughly, a third of the children presented lower respiratory tract complications as viral 93 
pneumonia and bronchiolitis. Viral pneumonia was more frequently reported in severe phenotype 94 
(p=0.004), while admission rate to ICU was equally distributed among these patients. Chest X-ray 95 
was performed in 77 patients (65%) on admission and infiltrates were found in 38 out 77 (50%). 96 
Respectively 20 and 15 patients had bilateral and mono-lateral infiltrates, for 3 of them it was not 97 
specified. In 4 out of 77 (5.2%) atelectasis and pleural effusion were found. The presence of 98 
infiltrates at the chest X-Ray did not correlate with severity clinical score or ICU admission rate 99 
(p=0.125 and p=0.71 Fisher exact test respectively). 100 
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Discussion 101 
In the present study we reported that most SARS-COV-2 infected children had fever and 102 
respiratory symptoms.  Similarly, Shekerdemian et al. reported that most of the patients included 103 
in   the North American Pediatric Intensive Care Unit (PICU) cohort presented respiratory 104 
symptoms, but they also state that only one child of their cohort presented gastrointestinal 105 
symptoms, speculating that these may be associated with milder clinical presentation (4). 106 
In children, common circulating HCoVs can cause gastrointestinal symptoms in up to 57% of cases, 107 
and this presentation is more common in children than adults (5). Increasing evidence showed 108 
that the gastrointestinal tract may represent a target for SARS-CoV-2 due to the expression of the 109 
angiotensin-converting enzyme 2 (ACE2), a major virus receptor. We reported, differently to 110 
published data, that a history of GS was positively correlated with a worst severity score (severe 111 
and critical) and a higher ICU admission rate. The same result was found, in an pooled analyses of 112 
adult cohorts, where GS were correlated to increased odds of critical disease and higher 113 
prevalence of complications (6).  114 
Interestingly, in our cohort having GS was more frequently reported in patients who developed 115 
cardiac impairment as complications of SARS-CoV-2 infection. The development of 116 
hyperinflammatory syndromes and Kawasaki-like disease in children exposed to SARS-CoV-2 117 
infection has been recently brought to attention. Riphagen et al. reported eight cases of 118 
hyperinflammatory syndrome with cardiac involvement, all of them presenting with fever and 119 
significant gastrointestinal symptoms (diarrhea, vomit, abdominal pain) (7), according to our 120 
current results and to what we have previously reported (8).  121 
In recent studies (4,9) comorbidities have been frequently reported in patients requiring 122 
admission to ICU. In the North American PICU cohort, authors reported that up to the 80% of 123 
patients included had comorbidities. The most common comorbidity reported was medically 124 
complex defined as long term dependence on technological support(4). In agreement with this 125 
cohort,  Parri and colleagues, in a SARS-COV-2 positive cohort of pediatric patients admitted at 126 
Italian Emergency Departments, reported that 9 patients out of 100 need mechanical ventilation 127 
and, among them, 6 (66%) had comorbidities (9).  128 
In the present study only 20 (16%) children with previous medical condition were included, 3 of 129 
them required ICU. The presence of preexisting medical conditions was not different in severe and 130 
critical patients when compared to mild, moderate and asymptomatic ones. Moreover, the ICU 131 
admission rate was similar in patients with and without comorbidities.   132 
 6 
There are several limitations to our study. First, the limited sample size. Second, children have 133 
been classified using a severity score previously applied to other pediatric cohorts, which is mainly 134 
designed on respiratory symptoms and lung involvement. The score criteria could explain the 135 
higher frequency of viral pneumonia among severe phenotype but not among patients requiring 136 
ICU admission. However, critical cases are defined not only by the progression to respiratory 137 
failure (ARDS) but also to life threating organ dysfunction (shock, myocardial injury, acute kidney 138 
injury). Therefore, in the present study the subset of critical patients includes not only patients 139 
with respiratory failure but also with other life-threating conditions.  Finally, there are evidences 140 
that COVID-19 related multisystemic inflammatory syndrome could be a complication in the 141 
disease spectrum. Although a better understanding of timing between GS and its onset would be 142 
of great interest, we could not provide such information in the current study.  143 
Conclusions 144 
The intention of this short report is to bring to attention that COVID-19 disease spectrum in 145 
children is far from been described in a universally shared way.  Other manifestations from 146 
respiratory are often the cause of severe illness, as we reported. Having preexisted medical 147 
conditions is not associated with worse outcome and consequently, severe clinical presentation 148 
must be considering also in previously healthy children. 149 
Gastrointestinal symptoms seem to be a clinical warning for children evaluated in any clinical 150 
settings when SARS-CoV-2 infection is suspected, independently of comorbidities.  151 
Pathogenetic mechanisms causing severe phenotypes in SARS-CoV-2 infected children need to be 152 
deepened by multidisciplinary approach as well we need more data to define a suitable clinical 153 
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AGE MEDIAN (IQR, y) 1.6 (0.3, 7.9) 4.3 (0.3, 10.1) 0.393
b




    
0.845 
    
0.854 
Newborn 5 4.7 1 5.0 
 
6 5.4 0 0.0 
 
Infant 44 41.1 7 35.0 
 
44 39.6 3 37.5 
 
Children 42 39.2 8 40.0 
 
46 41.4 3 37.5 
 
Adolescent 16 15.0 4 20.0 
 
15 13.5 2 25.0 
 
MALE 68 64.2 14 70.0 0.799 71 64.5 5 62.5 1.000 
PRESENTATION 
          
Fever 85 79.4 20 100.0 0.023 92 82.9 8 100.0 0.352 
RESP SYMPTOMS 68 63.6 14 70.0 0.799 74 67.3 4 50.0 0.441 
Respiratory Symptoms 
Only 
46 43.0 7 35.0 0.624 44 39.6 2 25.0 0.468 
Cough 52 48.6 9 45.0 0.812 57 51.4 2 25.0 0.812 
Rhinorrhea 43 40.2 6 30.0 0.460 46 41.4 0 0.0 0.022 
Wheezing 4 3.7 0 0.0 1.000 3 2.7 0 0.0 1.000 
Dyspnea 5 4.7 5 25.0 0.009 7 6.4 2 25.0 0.114 
GI SYMTOMPS 26 24.3 10 50.0 0.029 31 27.9 4 50.0 0.232 
GI Symptoms Only 13 12.1 5 25.0 0.160 14 12.6 3 37.5 0.087 
Vomit 6 5.6 6 30.0 0.004 6 5.4 6 75.0 0.004 
Diarrhea 20 18.7 8 40.0 0.044 20 18.0 8 100 0.044 
Abdominal Pain 6 5.6 2 10.0 0.611 8 7.2 0 0.0 1.000 
COMORBIDITIES 14 13.1 6 30.0 0.088 16 14.4 3 37.5 0.115 
Chronic Cardiac 
Conditions 
3 2.8 2 10.0 0.176 4 3.6 1 12.5 0.298 
Gastrointestinal 
Disorder 
2 1.9 2 10.0 0.117 2 1.8 1 12.5 0.190 
Obese 1 0.9 2 10.0 0.064 3 2.7 0 0.0 1.000 
Chronic Kidney Disease 2 1.9 0 0.0 1.000 2 1.8 0 0.0 1.000 
Chronic Neurological 
Disease 
0 0.0 2 10.0 0.024 1 0.9 0 0.0 1.000 
Immunological Condition 2 1.9 0 0.0 1.000 1 0.9 0 0.0 1.000 
CXR POSITIVE 25 43.9 13 65.0 0.125 35 51.5 3 37.5 0.711 
COMPLICATION 23 21.5 19 95.0 <0.001 35 31.5 7 87.5 0.003 
Viral pneumonia 16 15.0 9 45.0 0.004 24 21.6 1 12.5 0.468 
Bronchiolitis 8 7.5 1 5.0 0.570 9 8.1 0 0.0 0.522 
Bacterial pneumonia 0 0.0 2 10.0 0.024 1 0.9 1 12.5 0.130 
ARDS 0 0.0 2 10.0 0.024 1 0.9 1 12.5 0.130 
Pleural effusion 0 0.0 1 5.0 0.157 0 0.0 1 12.5 0.067 
Myocardial involvement 0 0.0 6 30.0 <0.001 2 1.8 4 50.0 <0.001 
Bacteremia 0 0.0 1 5.0 0.157 0 0.0 1 12.5 0.067 
Coagulation disorder 0 0.0 1 5.0 0.157 0 0.0 1 12.5 0.067 
AKI 0 0.0 1 5.0 0.157 0 0.0 1 12.5 0.067 
Liver dysfunction 0 0.0 1 5.0 0.157 0 0.0 1 12.5 0.067 
Myositis 1 0.93 0 0.0 0.843 1 0.9 0 0.0 0.933 
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